AML in Patients Aged ≥75 or with Pre-existing Organ Disease When Initial Therapy Did Not Achieve Response

Clinical Scenario

This protocol addresses newly diagnosed acute myeloid leukaemia in patients who are not eligible for intensive induction — specifically those aged 75 years or older, those with an ECOG performance score of 3 or above, or those with pre-existing heart, kidney, lung, or liver disease. These factors are among the strongest predictors of non-relapse induction-related mortality and define this population as unsuitable for standard intensive chemotherapy.

Previous Treatment & Failure Condition

Initial management in this setting used a hypomethylating agent — azacitidine or decitabine — as first choice, or low-dose cytarabine as an alternative (except in patients with adverse-risk cytogenetics, where low-dose cytarabine has very poor activity).

Escalation to this protocol is triggered when the patient has not responded or derived clinical benefit after at least 4 consecutive cycles of hypomethylating agent therapy.

Next-Line Approach — Partial Overview

For patients who do achieve a response to initial therapy, the structured next evaluation step involves reassessing eligibility for a potentially curative transplant-based approach using modified, less intensive conditioning. Whether a given patient qualifies — and the full decision pathway — is detailed in the complete protocol.

Instant Access to Structured Evidence-Based Regimens

References

Pre-existing heart, kidney, lung or liver disease, mental illness, an Eastern Cooperative Oncology Group (ECOG) performance score 3 and age 75 years are the strongest predictors for nonrelapse induction-related mortality and should be considered to determine ineligibility to intensive induction and consolidation ChT [V, B].

The HMAs azacitidine and decitabine are currently the first choice in newly diagnosed unfit AML patients [II, B].

Patients responding to initial treatment should be re-evaluated regarding their ability to undergo alloHCT using RIC, which may cure a proportion of these patients.

View source ↗